These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8553344)

  • 1. [Calcium antagonists in the treatment of hypertension and heart failure. A comment to recently published results of clinical trials].
    Kjeldsen SE; Westheim AS
    Tidsskr Nor Laegeforen; 1996 Jan; 116(1):77-80. PubMed ID: 8553344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An overview of hypertension studies with calcium antagonists].
    Kjeldsen SE; Midtbø K; Os I; Westheim A
    Tidsskr Nor Laegeforen; 1999 May; 119(13):1878-82. PubMed ID: 10382332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Status of ongoing controlled clinical trials on hypertension].
    Kjeldsen SE; Syvertsen JO; Lund-Johansen P
    Tidsskr Nor Laegeforen; 1996 Jan; 116(1):61-3. PubMed ID: 8553340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Are newer antihypertensive agents better than the older ones? Results of trials (CAPPP, STOP-2, NORDIL, INSIGHT and ALLHAT) with newer antihypertensive agents].
    Hildebrandt PR; Tuxen CD; Kjeldsen SE; Lund-Johansen P; Hansson L
    Ugeskr Laeger; 2001 Dec; 164(1):18-21. PubMed ID: 11810791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained-release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use.
    Silvestry FE; St John Sutton MG
    Eur Heart J; 1998 Aug; 19 Suppl I():I8-14. PubMed ID: 9743438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies.
    Opie LH; Yusuf S; Kübler W
    Prog Cardiovasc Dis; 2000; 43(2):171-96. PubMed ID: 11014332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of calcium channel blockers in hypertension.
    Conlin PR; Williams GH
    Adv Intern Med; 1998; 43():533-62. PubMed ID: 9506192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcium antagonists in the treatment of heart failure. Re-evaluation of therapeutic strategies].
    Gattis W; O'Connor CM
    Drugs; 2000; 59 Spec No 2():17-24. PubMed ID: 11002855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group.
    Van der Vring JA; Cleophas TJ; Van der Wall EE; Niemeyer MG
    Am J Ther; 1999 Jul; 6(4):229-33. PubMed ID: 11329102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should calcium antagonists be first line drugs in hypertension?
    Furberg CD; Psaty BM
    Herz; 1995 Dec; 20(6):365-9. PubMed ID: 8582696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Differential therapy with calcium antagonists].
    Scholze JE
    Herz; 2003 Dec; 28(8):754-63. PubMed ID: 14689111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel blockers in treatment of hypertension.
    Muntwyler J; Follath F
    Prog Cardiovasc Dis; 2001; 44(3):207-16. PubMed ID: 11727278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.